aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

NEXT STORY
Prelude Therapeutics Announces Launch of Proposed Public Offering
PREV STORY
Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology

CAMBRIDGE, Mass. and BEIJING, China, Sept. 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

author_avatar
NASDAQ Market News

Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights

- Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 ...

author_avatar
NASDAQ Market News

Tetraphase Pharmaceuticals Initiates Phase 1 Clinical Trial for TP-271

WATERTOWN, Mass., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced ...

author_avatar
NASDAQ Market News